Big Pharma has a $300 billion problem, and biotech developers with promising drugs are becoming the fix. Major drugmakers are spending at a pace not seen since 2019 to replace medicines that will soon lose patent protection.

etftrends.com - 2026-07-13 17:06:04

Are AVB, LPRO, APGE, TMHC Obtaining Fair Deals for their Shareholders? PR Newswire NEW YORK, July 6, 2026

gurufocus.com - 2026-07-06 21:00:00

/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws

prnewswire.com - 2026-07-06 20:02:00

MILWAUKEE, July 02, 2026 (GLOBE NEWSWIRE) -- Ademi LLP is investigating Apogee (NASDAQ: APGE) for possible breaches of fiduciary duty and other violations of law in its recently announced transaction with CRH. Click here to learn how to join our investigation and obtain additional information or contact us at gademi@ademilaw.

globenewswire.com - 2026-07-02 05:34:34

MILWAUKEE, July 02, 2026 (GLOBE NEWSWIRE) -- Ademi LLP is investigating Apogee (NASDAQ: APGE) for possible breaches of fiduciary duty and other violations of law in its recently announced transaction with CRH.

globenewswire.com - 2026-07-02 05:34:00

AbbVie knows how to plan ahead.

fool.com - 2026-06-30 15:45:00

LLY, ABBV, BIIB and JNJ hit new 52-week highs as biotech rallies, with company-specific pipeline, approvals and deal activity adding momentum.

zacks.com - 2026-06-29 12:11:05

Are TECH, APGE, BOLD, REFI Obtaining Fair Deals for their Shareholders? PR Newswire NEW YORK, June 25, 2026

gurufocus.com - 2026-06-25 14:00:00

After a sweeping semi-annual rebalance, the biotech index underlying the ALPS Medical Breakthroughs ETF (SBIO) gained over 10% in just six trading days beginning June 18. Key Takeaways: SBIO's underlying index gained 10.01% in six trading days following its June 18 semi-annual rebalance.

etftrends.com - 2026-06-25 11:31:47

The pharmaceutical company gains a prospective blockbuster with the deal, but is it worth $10.9 billion?

fool.com - 2026-06-25 09:53:00

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of [url="]Kahn Swick and Foti[/url], LLC (“KSF”) are investigating the propo

gurufocus.com - 2026-06-24 15:00:00

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Apogee Therapeutics, Inc. (NasdaqGM: APGE) to AbbVie (NYSE: ABBV). Under the terms of the proposed transaction, shareholders of Apogee will receive $135.11 in cash for each share of Apogee that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequa.

businesswire.com - 2026-06-24 14:25:00

Pre-Market Stock Futures: Futures are trading higher this morning, but if you've ever heard the old saying, "when the chips are down", that was the poster child phrase for Tuesday's session, as technology stocks, and specifically the semiconductor stocks, followed a worldwide sell-off that initially began in Korea and carried around the globe. When... Here Are Wednesday's Best Wall Street Analyst Research Calls: Devon Energy, Flowserve, Klaviyo, Macerich, Merck, Nucor, Take-Two Interactive Software, Twilio, and More

247wallst.com - 2026-06-24 08:15:12

Nova Minerals Corp (ASX:NVA, NYSE-A:NVA, FRA:QM30) has completed its redomicile to the United States and started key 2026 field work at its Estelle Gold and...

proactiveinvestors.com - 2026-06-23 08:23:00

G50 Corp Ltd (ASX:G50, OTCQB:GFYTF) has delivered a strong first result from its 2026 core drilling program at the White Caps Gold Project in Nevada,...

proactiveinvestors.com - 2026-06-23 07:32:00

Empire Metals Ltd (AIM:EEE, OTCQX:EPMLF), the AIM-quoted and OTCQX-traded exploration and development company, will present to investors on 30 June....

proactiveinvestors.com - 2026-06-23 04:08:00

Metals One PLC (AIM:MET1, FRA:HT7, OTCQB:MTOPF), the gold and uranium developer and investor, has built a 5.57% stake in Talon Resources. The holding was...

proactiveinvestors.com - 2026-06-23 03:25:00

On June 22, 2026, Apogee Therapeutics shares surged as investors reacted to AbbVie's proposed acquisition terms.

fool.com - 2026-06-22 17:54:24

NEW YORK, June 22, 2026 /PRNewswire/ -- Class Action Attorney  Juan Monteverde  with Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2025 ISS Securities Class Action Services Report. The firm is headquartered at the Empire State Building in New York City and is investigating Apogee Therapeutics, Inc. (NASDAQ: APGE ) related to its sale to AbbVie Inc. Under the terms of the proposed transaction, Apogee shareholders are expected to receive $135.11 per share in cash.

prnewswire.com - 2026-06-22 14:59:00

4:15pm: Big Tech selloff US stocks finished mixed on Monday as steep losses in some of the market's biggest technology names outweighed gains across much of...

proactiveinvestors.com - 2026-06-22 12:18:00

U.S. stocks were higher, with the Dow Jones index gaining more than 200 points on Monday.

benzinga.com - 2026-06-22 12:08:40

AbbVie Inc. (NYSE:ABBV) announced Monday that it has agreed to acquire Apogee Therapeutics (NASDAQ:APGE) in a cash deal valued at approximately $10.9 billion.

benzinga.com - 2026-06-22 12:05:50

MILWAUKEE, June 22, 2026 /PRNewswire/ -- Ademi LLP is investigating Apogee (NASDAQ: APGE) for possible breaches of fiduciary duty and other violations of law in its recently announced transaction with CRH. Click here to learn how to join our investigation and obtain additional information or contact us at [email protected] or toll-free: 866-264-3995.

prnewswire.com - 2026-06-22 11:35:00

AbbVie (ABBV) shares rose by 6% following its agreement to acquire Apogee Therapeutics (APGE), which saw a remarkable 47% increase in its stock price. The acqu

gurufocus.com - 2026-06-22 11:14:00

2:30pm: Market movers Alphabet Inc (NASDAQ:GOOG) shares fell 5.5% after the company lost key AI researcher Noam Shazeer to OpenAI, fueling investor concerns...

proactiveinvestors.com - 2026-06-22 10:33:00

Bloomberg Intelligence's Sam Fazeli discusses AbbVie's $10.9 billion acquisition of Apogee Therapeutics. The deal enhances AbbVie's presence in dermatology by adding treatments for atopic dermatitis, commonly known as eczema, to its portfolio.

youtube.com - 2026-06-22 10:15:03

Abbvie Inc (NYSE:ABBV) announced that it will acquire Apogee Therapeutics (NASDAQ:APGE) in an all-cash transaction valued at approximately $10.9 billion, adding a pipeline of clinical-stage therapies for inflammatory and immunological diseases, including atopic dermatitis and asthma. Under the terms of the definitive agreement announced Sunday, AbbVie will acquire all outstanding Apogee shares for $135.11 per share in cash.

proactiveinvestors.com - 2026-06-22 10:07:55

Halper Sadeh LLC, an investor rights law firm, is investigating the sale of Apogee Therapeutics, Inc. (NASDAQ: APGE) to AbbVie for $135.11 per share in cash.Hal

gurufocus.com - 2026-06-22 10:00:00

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating the sale of Apogee Therapeutics, Inc. (NASDAQ: APGE) to AbbVie for $135.11 per share in cash.Halper Sadeh encourages Apogee shareholders to click here to learn more about their rights and options or contact Daniel Sadeh or Zachary Halper free of charge at (212) 763-0060 or [email protected] or [email protected] investigation concerns whether Apogee and its board of directors violated the fede.

businesswire.com - 2026-06-22 09:22:00

Stock futures are cautiously higher as investors asses U.S.-Iran war negotiations

schaeffersresearch.com - 2026-06-22 09:11:00

Stocks are having a quiet morning Monday as investors come off a long holiday weekend with a close eye on peace talks between the U.S. and Iran; a second day of negotiations in Switzerland has reportedly concluded after renewed threats against Iran from President Trump and continued attacks in Lebanon by Israel made for an eventful first day of talks; earnings from FedEx and Micron are on tap this week, along with the release of the Fed's preferred measure of inflation; SpaceX shares are poised to start this week with a third straight day of declines; and shares of Apogee Therapeutics are soaring on news it is being acquired by AbbVie for $11 billion. Here's what you need to know today.

investopedia.com - 2026-06-22 08:56:12

AbbVie has agreed to buy Apogee Therapeutics for about $10.9 billion in cash in a deal that bolsters the biopharmaceutical company's immunology and inflammation portfolio.

wsj.com - 2026-06-22 07:42:00

AbbVie reportedly set to take over Apogee, Satya Nadella wants to upturn AI, and more

fool.com - 2026-06-22 07:30:00

AbbVie will acquire the clinical-stage biotech's pipeline of candidates for inflammatory and immunological diseases.

barrons.com - 2026-06-22 07:06:00

AbbVie ​will acquire ‌biotech ​Apogee ​Therapeutics for $10.9 ⁠billion ​in ​cash, they said ​on ​Monday, as ‌the ⁠company builds its ​next-generation ​immunology ⁠pipeline.

reuters.com - 2026-06-22 07:04:38

Proposed acquisition adds a diverse pipeline of assets focused on elevating the standard of care for patients with dermatologic, respiratory and other related inflammatory and immunological diseases Apogee's lead asset, zumilokibart (APG777), is a late-stage, half-life extended monoclonal antibody targeting IL-13, in development for patients with atopic dermatitis Apogee's pipeline also includes combinations of its novel antibodies; APG273, a potential best-in-category long-acting combination targeting IL-13 and thymic stromal lymphopoietin (TSLP), is being developed in asthma Apogee shareholders to receive $135.11 per share in cash, for a total equity value of approximately $10.9 billion AbbVie to hold investor conference call today, June 22, at 8:00 a.m. CT NORTH CHICAGO, Ill.

prnewswire.com - 2026-06-22 07:00:00

10:50am: AbbVie snaps up Apogee for nearly $11B Abbvie Inc (NYSE:ABBV) (Abbvie Inc (NYSE:ABBV)) announced that it will acquire Apogee Therapeutics...

proactiveinvestors.com - 2026-06-22 06:55:00

Intel and Micron stocks are heading for further records, while SpaceX, Alphabet, and other big tech names decline.

barrons.com - 2026-06-22 05:56:00

AbbVie is nearing a deal to acquire inflammatory disease drug developer Apogee Therapeutics ​for about $10.9 billion in cash, the Financial ‌Times reported on Friday, citing people familiar with the matter.

reuters.com - 2026-06-19 11:17:12

Apogee Therapeutics NASDAQ: APGE executives outlined plans to advance zumilokibart, the company's IL-13-targeting antibody, into late-stage development for atopic dermatitis while expanding the program into asthma and eosinophilic esophagitis, during a Goldman Sachs discussion hosted by lead biotechnology equity research analyst Salveen Richter.

marketbeat.com - 2026-06-10 22:05:04

Apogee Therapeutics, Inc. (APGE) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

seekingalpha.com - 2026-06-10 15:52:09

Apogee Therapeutics NASDAQ: APGE executives said the company is preparing to move its lead drug candidate, zumilokibart, into Phase 3 testing later this year after reporting Phase 2b data in atopic dermatitis and securing a major financing agreement with Blackstone.

marketbeat.com - 2026-06-04 05:04:57

Apogee Therapeutics, Inc. (APGE) Discusses Positive Part B Results From Phase 2 APEX Trial of Zumilokibart in Atopic Dermatitis Transcript

seekingalpha.com - 2026-06-01 16:54:05

SAN FRANCISCO and BOSTON, May 28, 2026 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), today announced that members of management will participate at the following investor conferences.

globenewswire.com - 2026-05-28 16:01:00

Apogee Therapeutics, Inc. remains a Buy, driven by zumilokibart's potential in atopic dermatitis and recent positive Phase 2b data. Zumilokibart's efficacy matches leading biologics, with the key differentiator being 2–4 annual doses, pending maintenance data in 2025. The Blackstone collaboration secures up to $1.3B in funding, eliminating near-term dilution risk and supporting commercialization.

seekingalpha.com - 2026-05-28 15:01:16

Apogee Enterprises (NASDAQ:APOG) has entered a strategic financing collaboration with Blackstone Life Sciences for up to $1.3 billion in non-dilutive capital, combining up to $800 million in synthetic royalty financing with as much as $500 million in senior corporate debt, giving the immunology developer runway to advance Phase 3 development and potential commercialization of its lead candidate zumilokibart. The financing structure pairs royalty-based capital tied to future product revenue with senior debt capacity.

proactiveinvestors.com - 2026-05-28 14:50:15

Blackstone (BX) is providing as much as $1.3 billion in financing to Apogee Therapeutics (APGE), giving the biotech company fresh capital to push zumilokibart t

gurufocus.com - 2026-05-27 13:33:00

Up to $1.3 billion in flexible, non-dilutive capital, including up to $800 million of synthetic royalty and access of up to $500 million in senior corporate debt

globenewswire.com - 2026-05-27 06:31:00

APEX Part B met all primary and secondary endpoints with high statistical significance; mid-dose zumilokibart planned to advance into Phase 3 trials in moderate-to-severe atopic dermatitis (AD) in 2H 2026

globenewswire.com - 2026-05-27 06:30:00

SAN FRANCISCO and BOSTON, May 26, 2026 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company advancing optimized, novel biologics with potential for best-in-class profiles in the largest inflammatory and immunology (I&I) markets, today announced it will report Part B 16-week data from the Phase 2 APEX trial of zumilokibart on Wednesday, May 27, 2026. Following the announcement, the company will host a conference call and webcast at 8:00 a.m.

globenewswire.com - 2026-05-26 16:01:00